The team began with a striking natural experiment built into Chinese pig genetics. Ningxiang pigs are an indigenous breed that is notably prone to accumulating fat, while commercial Duroc-Landrace-Yorkshire pigs remain comparatively lean under the same conditions. By comparing the gut microbiomes of these two breeds, the researchers found that the adiposity-prone Ningxiang animals carried an expanded population of Gram-negative bacteria, elevated levels of lipopolysaccharide, or LPS, in their circulation, and markedly reduced abundance of Clostridium butyricum, a beneficial gut bacterium, along with reduced levels of its signature metabolite, butyrate. LPS is a structural component of the outer membrane of Gram-negative bacteria, and when it leaks from a dysbiotic gut into the bloodstream it is recognized by the immune system as a danger signal, triggering chronic low-grade inflammation that is a hallmark of obesity.

To test whether these microbial differences were a cause rather than a consequence of fatness, the researchers performed fecal microbiota transplantation, transferring gut microbes from obese-prone Ningxiang donors into lean Duroc-Landrace-Yorkshire recipients. The lean pigs gained adiposity after receiving the microbiota of their fat-prone counterparts, and the transfer was accompanied by a significant drop in colonization by C. butyricum. This result suggested that the microbial community itself, depleted of butyrate-producing organisms and enriched in LPS-carrying Gram-negative species, could actively transmit a tendency toward weight gain.

The next step was intervention. In mice fed a high-fat diet, supplementation with C. butyricum and with butyrate itself effectively restored gut microbial homeostasis and ameliorated obesity. These findings established the bacterium and its metabolite as candidate therapeutic agents, but they left open the central question of mechanism: through what molecular circuitry does a gut microbe influence whole-body fat accumulation? To answer it, the team turned to large-scale transcriptomics, sequencing the RNA of multiple organs in both pigs and long-tailed macaques, a nonhuman primate, to search for gene regulatory programs conserved across species.

The search converged on a single transcription factor: early growth response 1, or EGR1. Across organs and across species, EGR1 emerged as a central regulator of obesity-associated inflammation, with consistent enrichment of the PI3K-Akt signaling pathway, a well-known intracellular cascade that controls cell growth, survival and metabolism. Single-cell RNA sequencing then sharpened the picture at the level of individual immune cells. Macrophages, the tissue-resident immune cells that infiltrate expanding fat tissue in obesity, showed a clear dichotomy: those with high EGR1 expression adopted a pro-inflammatory M1 phenotype, pumping out inflammatory cytokines, while those with low EGR1 expression displayed an anti-inflammatory M2 profile associated with tissue repair and metabolic calm. In obese adipose tissue, the balance tips toward the EGR1-high, M1-polarized state, and that shift is thought to be a major driver of insulin resistance and metabolic dysfunction.

To establish that EGR1 was not merely a bystander, the researchers used two complementary strategies. First, they performed an in silico knockout, computationally removing EGR1 from gene regulatory networks built from macrophage-specific expression data, and found that PI3K-Akt signaling depended functionally on EGR1 downstream. Second, they applied a pharmacological inhibitor of EGR1, designated EGR1i and known as IT25, and observed the same disruption of the pathway. Together, the computational and chemical perturbations supported a model in which EGR1 sits upstream of PI3K-Akt signaling within macrophages, orchestrating the inflammatory program that links gut-derived LPS to metabolic inflammation.

Integrating metagenomic data on microbial communities with single-cell data on immune cells, the team proposed what they call a conserved LPS-EGR1 axis governing macrophage polarization in obesity. According to this model, gut dysbiosis increases the translocation of LPS into the circulation, LPS activates EGR1 expression in macrophages, and EGR1 drives those macrophages toward the M1 state through PI3K-Akt-associated signaling, thereby sustaining the chronic inflammation that characterizes obesity. The loop is self-reinforcing: inflammation worsens gut barrier integrity, which permits more LPS to enter, which further activates the axis.

To validate the model experimentally rather than merely infer it from correlations, the researchers built two purpose-made systems. The first was a mouse model of obesity in which a high-fat diet was potentiated with LPS, mimicking the endotoxemia seen in dysbiotic guts. The second was a cell culture model in which LPS was used to drive M1 polarization of RAW264.7 macrophages, a widely used mouse macrophage cell line. Into these systems they introduced four candidate disruptors of the axis: live C. butyricum, butyrate, the amino acid arginine, and the EGR1 inhibitor IT25. All four treatments significantly attenuated weight gain in the animal model, downregulated EGR1 expression, and suppressed M1 macrophage polarization, restoring a healthier M1/M2 balance. The beneficial effects were accompanied by significant alterations in genes related to the PI3K-Akt pathway, suggesting that this pathway acts in concert with EGR1 within the regulatory network rather than as an independent route.

The inclusion of arginine among the effective interventions adds an intriguing nutritional dimension to the work. Arginine is a semi-essential amino acid with known immunomodulatory and nitric-oxide-related functions, and its ability to blunt the LPS-EGR1 axis alongside a probiotic bacterium, a short-chain fatty acid and a targeted inhibitor suggests that the axis is a convergent point where diet, microbes and pharmacology all meet. For a field in which probiotic studies often report benefits without clear mechanisms, the strength of this study lies in its chain of evidence: a natural cross-breed comparison, a transplantation experiment, a dietary intervention, cross-species transcriptomics, single-cell resolution, computational and chemical perturbation, and finally purpose-built validation models. Each link in the causal chain from dysbiosis to inflammation to fat accumulation was tested separately.

The cross-species consistency is equally significant. Because the EGR1-centered program was observed in pigs, mice and macaques, the LPS-EGR1 axis appears to be a fundamental feature of mammalian metabolic inflammation rather than a quirk of any one model organism. That conservation raises the stakes for translation. If the same axis operates in humans, and the components are plausible given the well-documented role of endotoxemia and M1 macrophage infiltration in human obesity, then C. butyricum, butyrate, arginine supplementation or EGR1-targeted drugs could eventually complement existing strategies for metabolic disease. The authors note that the work was supported by the National Natural Science Foundation of China and several Hunan provincial programs, and the study was approved by the Biomedical Research Ethics Committee of Hunan Normal University. Much remains to be done, including direct demonstration of the axis in human tissues and safety testing of EGR1 inhibition, which is a transcription factor with roles in many cell types. But the study delivers something the obesity field has lacked: a single, targetable molecular hub, EGR1, that connects the gut microbiota to the immune cells that set the inflammatory tone of fat tissue. In doing so, it transforms a diffuse association between microbes and obesity into a defined circuit with identifiable points of intervention, and it suggests that reshaping the gut ecosystem with the right bacterium, or simply feeding it the right substrate, may be enough to quiet the inflammation that makes fat so metabolically dangerous.

Subject of Research: How Clostridium butyricum and butyrate modulate macrophage polarization via the LPS-EGR1 axis to alleviate obesity

Article Title: Clostridium butyricum and butyrate reprogram macrophages to alleviate obesity by disrupting the LPS-EGR1 axis and its associated PI3K-Akt signaling

Article References: Li, W., Chen, W., Wang, L., Zhu, Q., Zhang, Y., Zeng, X., Liu, J., Wang, Q., Ma, H., Yin, J., Li, J., Yin, Y., & Yang, H. (2026). Clostridium butyricum and butyrate reprogram macrophages to alleviate obesity by disrupting the LPS-EGR1 axis and its associated PI3K-Akt signaling. Microbiome. https://doi.org/10.1186/s40168-026-02554-y

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02554-y

Keywords: Clostridium butyricum, butyrate, gut microbiota, obesity, LPS, EGR1, macrophage polarization, PI3K-Akt signaling, inflammation, fecal microbiota transplantation, metabolic disease, single-cell RNA sequencing

The finding matters because gestational diabetes affects a substantial share of pregnancies worldwide and raises risks for both mother and child, including future type 2 diabetes. Previous observational work had already hinted that pregnant women who develop the condition tend to have lower levels of butyrate in their circulation. What remained unclear was whether this deficiency was merely a byproduct of the disease or a genuine driver of it, and if the latter, through which molecular route butyrate might act. The new study set out to answer both questions with a combination of human data, animal experiments and mechanistic work at the level of chromatin.

The clinical arm of the study was a nested case-control analysis that measured serum butyrate and active GLP-1, the glucagon-like peptide-1 hormone released by intestinal cells after meals to stimulate insulin secretion, in pregnant women. The results were striking in their consistency: women who went on to develop gestational diabetes had significantly lower levels of both butyrate and active GLP-1, and this difference was detectable not only in mid-pregnancy, when the condition typically manifests, but already in early pregnancy. That early timing is important, because it suggests that a depleted butyrate-GLP-1 axis precedes the onset of disease rather than simply following from it, raising the possibility of prediction and even prevention.

To test causality, the team turned to a mouse model of gestational diabetes induced by a high-fat diet combined with antibiotics, a regimen that disrupts the gut microbial community and mimics the metabolic disturbances seen in patients. When the animals received a probiotic supplement of Clostridium butyricum, a bacterium renowned for its butyrate production, their metabolic picture improved markedly. Hyperglycaemia eased, insulin resistance declined, and perhaps most intriguingly, the disruption of circadian glucose rhythms that accompanies gestational diabetes was partially corrected. Microbial profiling of the treated animals confirmed that the supplement enriched the community of butyrate-producing bacteria and raised systemic butyrate levels, tying the metabolic benefits directly to the microbial metabolite.

The mechanistic heart of the study lies in the colon. Butyrate has long been known to act as an inhibitor of histone deacetylases, enzymes that remove acetyl groups from histone proteins and, in doing so, keep stretches of DNA tightly packed and transcriptionally silent. When the researchers examined colon tissue from the treated mice, they found that Clostridium butyricum supplementation reduced the abundance of one particular deacetylase, HDAC3, and increased the global acetylation of histone H3 at lysine 27, a chemical mark known as H3K27ac that flags active genes and their regulatory elements. In other words, the microbial metabolite appeared to be physically opening up the genome in intestinal cells.

Which genes were being opened? To find out, the team performed integrated RNA sequencing and H3K27ac chromatin immunoprecipitation sequencing in enteroendocrine cells, the hormone-producing specialists of the gut lining, treated with sodium butyrate and with agents that modulate HDAC3. The multi-omics analysis converged on a single compelling candidate: secretagogin, or SCGN, a calcium-binding protein expressed in enteroendocrine cells. Butyrate enhanced both the transcription of SCGN and the deposition of H3K27ac at its promoter, indicating that the metabolite directly activates the gene through the same epigenetic mechanism. Because SCGN has been implicated in the regulated secretion of peptide hormones, the connection to GLP-1 was an obvious next step.

The functional experiments confirmed it. Treating enteroendocrine cells with butyrate, or knocking down HDAC3 with molecular tools, increased SCGN expression and boosted the secretion of GLP-1. Conversely, when the researchers forced cells to overexpress HDAC3, the SCGN-GLP-1 axis was suppressed, but this suppression could be reversed by co-treatment with butyrate. The epigenetic brake and the microbial metabolite were locked in a push-pull relationship: HDAC3 silences the hormone-secreting programme, and butyrate releases it. This is a textbook example of how a dietary and microbial signal can be translated into a durable change in gene expression, one that ultimately shapes whole-body metabolism.

Genetic validation in living animals provided the final, decisive test. The team used mice that carry only one functional copy of the HDAC3 gene, a condition known as haploinsufficiency, which reduces the protein’s levels without eliminating it entirely. If the benefits of Clostridium butyricum truly flow through HDAC3 inhibition, then animals with less HDAC3 to begin with should gain little from the probiotic. That is precisely what the researchers observed: in HDAC3-haploinsufficient mice, the metabolic improvements and the upregulation of SCGN driven by the bacterium were abolished. The genetic experiment closes the causal loop and rules out the possibility that butyrate works through unrelated pathways.

Taken together, the study delineates what the authors describe as a novel gut microbiota-epigenetic-hormonal axis. Gut bacteria produce butyrate; butyrate inhibits HDAC3 in the intestinal lining; HDAC3 inhibition raises H3K27ac at the SCGN promoter; SCGN activation potentiates GLP-1 secretion; and GLP-1 improves glucose homeostasis for mother and fetus. Each link in this chain was tested independently, from the human correlation through the mouse intervention to the chromatin-level biochemistry and the genetic knockout. The architecture of the pathway is elegant precisely because it is specific: rather than a diffuse anti-inflammatory effect, the metabolite acts on a defined enzyme at a defined genomic target to produce a defined hormonal outcome.

The translational implications are considerable. HDAC3 and the downstream SCGN-GLP-1 pathway now stand as candidate targets for preventing or treating gestational diabetes, whether through probiotic supplementation with butyrate-producing strains such as Clostridium butyricum, dietary strategies that favour butyrate-producing communities, or future drugs that modulate HDAC3 activity in the gut. The authors note that their work was supported by the Beijing Municipal Natural Science Foundation, the National Natural Science Foundation of China and related programmes, and the study was conducted under ethics approvals for both the human cohort and the animal experiments. As with any mouse study, the road to clinical application will require trials in pregnant women, but the early-pregnancy signature of low butyrate and low GLP-1 offers a tantalising window for intervention long before the disease declares itself. For a condition that shapes the lifelong metabolic health of two generations at once, a microbial molecule that rewrites gene expression in the gut may prove to be one of the most consequential discoveries in pregnancy metabolism in years.

Subject of Research: How the gut microbial metabolite butyrate improves gestational glucose homeostasis through HDAC3 inhibition and epigenetic activation of the SCGN/GLP-1 axis

Article Title: The gut microbiota-derived butyrate improves gestational glucose homeostasis through HDAC3 inhibition and epigenetic activation of the SCGN/GLP-1 axis

Article References: Han, W., Zhang, Y., Huang, J., Lu, Y., Yin, X., Zhao, Y., Yuan, X., Yang, R., Zhang, L., Zheng, W., & Li, G. (2026). The gut microbiota-derived butyrate improves gestational glucose homeostasis through HDAC3 inhibition and epigenetic activation of the SCGN/GLP-1 axis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08720-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08720-y

Keywords: gestational diabetes, butyrate, gut microbiota, HDAC3, epigenetics, GLP-1, secretagogin, Clostridium butyricum, histone acetylation, H3K27ac, enteroendocrine cells, insulin resistance